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insight in the activated pathways related to the progression of the
disease. Imaging mass spectrometry is ideally suited for this task as it
allows the generation of high resolution molecular images of a wide
variety of biological compounds from complex surfaces without the
need for chemical labels or antibodies. High ﬁdelity molecular ion
images can be generated using modern desorption and ionization
techniques combined with high end mass spectrometric systems. The
distribution of several hundreds of peptides and proteins on the surface
of histological tissue sections can be determined in a single imaging MS
experiment. This enables molecular pathway analysis and the role of
the different molecular signals and their behavior under a drastically
changing chemical or biological environment in these pathways.
The complexity of these pathways in diseases prohibits the detailed
chemical characterization by a single technique. We have developed an
approach that combines a number of innovative mass spectrometric
imaging approaches with bright ﬁeld imaging, magnetic resonance
imaging and targeted IHC images to reﬁne our understanding of oste-
oarthritis progression in human cartilage samples. In addition we have
integrated state-of-the-art quantitative proteomics and metabolomic
studies of selected tissues in our molecular imaging workﬂow. The
common histological tools typically only provide generic morphological
information unless immunohistochemistry is used to determine the
distribution one speciﬁc known protein. Imaging mass spectrometry
has evolved to bring these two disciplines, mass spectrometry and
histology. This approach, sometimes referred to as molecular histology,
can take great beneﬁt from the use of high resolution mass spectrom-
etry, gas-phase ion mobility separation and smart surface preparation
protocols. In an OA study we have created maps of peptide distribution
at 150 um of pixel size in control and OA human cartilage. We have
identiﬁed and localized proteins such as biglycan (PGS1), prolargin
(PRELP), decorin (PGS2) and aggrecan core protein (PGCA). Protein
markers speciﬁc to the OA pathology have been additionally imaged.
Cartilage oligomeric matrix protein (COMP) and ﬁbronectin (FINC)
peptides were exclusively found in the OA samples. Their distribution
displayed a stronger intensity in the deep compared to the superﬁcial
area. Combined they provide new molecular visualization tools for
biomedical researchers. These innovative developments towards high
resolution imaging mass spectrometry can reveal new tissue details
that remain hidden with conventional molecular imaging approaches.
In this contribution we will discuss applications of new chemical
microscopes in biomedical tissue analysis. This lecture will discuss how
imaging MS can elucidate the way in which local environments can
inﬂuence signaling pathways in diseases.
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IS IT TIME TO REVISIT THE SYMPTOMATIC OUTCOME VARIABLES TO
ASSESS OA TREATMENTS?
M. Dougados. René descartes Univ., Paris, France
1. The current conventional domains evaluating the symptoms of
patients suffering from osteoarthritis are mainly the ones of pain and
functional impairment. Some studies are incorporating also a patient/
physician global assessment. Such domains have been proposed by
physicians. Based on the experience of other rheumatic conditions (e.g.
rheumatoid arthritis) one could consider as relevant to revisit these
domains by asking the patients. Such patient's perspective might result
in different selection of domains.
2. Treatments in OA can be categorized in 2 mains categories: (a) the
ones aimed at improving the current patient's condition and (b) the one
aimed at preventing a subsequent poor condition.
The methodology used to assess drugs aimed at improving the patient's
condition is very well established despite the fact that some aspects
could be further improved such as (a) the phenotype of the recruited
patients (e.g. diagnostic criteria, severity scoring system, co-existence of
inﬂammation), (b) the study design and, in particular, the so-called
“withdrawal design”, “discontinuation trial”.
The methodology to assess the symptoms during OA trials evaluating
drugs aimed at preventing a subsequent poor condition is usually
similar than the one used to assess treatments aimed at improving the
patient's condition. This approach was and is responsible of some
disappointing results. It seems reasonable that the outcome variables
reﬂect the main objective of these treatment (e.g. prevention). There-
fore, the studies evaluating such potential treatments should use as an
outcome variable a poor condition or a not acceptable condition. Thiswas the rationale of the OARSI-OMERACT initiative which is now
proposing an outcome variable deﬁning such poor condition or not
acceptable condition. Such composite index is a combination of non
acceptable symptoms (pain and function) states observed during
a certain period of time (at least 2 consecutive visits 3 months a part)
together with a structural progression deﬁned by a worsening in the
joint space narrowing of at least 0.5 mm.
Prospective studies have to be further conducted in order to evaluate
the relevance and the feasibility of this proposal.
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CARTILAGE AND JOINT DEVELOPMENT
V. Lefebvre. Cleveland Clinic, Cleveland, OH
Osteoarthritis clinically manifests itself by joint pain, deformation, and
reduced mobility, and it is biologically characterized by progressive
and irreversible degeneration of articular cartilage. The disease has
major negative impact on affected individuals and the society as
a whole both because of its high prevalence and because of current
lack of cures. Today's treatments indeed focus on pain relief and
arthroplasty, but they are not curative, because efﬁcient procedures to
block cartilage degeneration and restore normal tissue structure and
function remain nonexistent. A key factor in the development of
osteoarthritis, which is also a major obstacle in the design of curative
treatments, is that adult articular chondrocytes virtually lack intrinsic
mechanisms to properly repair tissue damage. We therefore believe
that new strategies to cure osteoarthritis should be devised based on
recapitulating the mechanisms that lead chondrocytes to form artic-
ular cartilage during development and help the cells maintain tissue
homeostasis in early adult life. In this keynote lecture, we will review
current understanding of these mechanisms, and will focus on recent
discoveries and lingering gaps in knowledge. In particular, we will
present new data from our laboratory on the roles of Sox9 in chon-
drogenesis. Sox9 was previously demonstrated to be a pivotal tran-
scription factor in early chondrogenesis in the embryo, since it
commits multipotent mesenchymal cells to the chondrocyte lineage
and directly activates the early chondrocyte differentiation program.
While it was originally proposed that Sox9 might inhibit chondrocyte
proliferation and hypertrophic maturation in the cartilage growth
plate, we have found, by combining conditional knockout strategies in
the mouse with advanced molecular approaches, that Sox9 is actually
necessary for growth plate development. Sox9 sustains chondrocyte
proliferation, at least in part by preventing prehypertrophic differen-
tiation. It is then required to maintain the lineage fate of chondrocytes
by blocking differentiation of prehypertrophic cells into osteoblasts,
and it cooperates with the transcription factor Mef2c to directly
activate the hypertrophic chondrocyte program. Sox9 is thus a key
transcription factor throughout the differentiation program of fetal
chondrocytes. These ﬁndings suggest that Sox9 could have similar
roles in articular cartilage throughout life, and we will show prelim-
inary data from our laboratory that supports this hypothesis. We thus
propose that osteoarthritic conditions could lead to articular cartilage
degeneration as a result of Sox9 gene downregulation or as a result of
a switch in Sox9 protein activity, from promoting an articular
phenotype to activating a growth plate chondrocyte fate. Thus, while
curative strategies for osteoarthritis should promote expression of the
Sox9 gene, as a mandatory chondrogenic driver, they should also
ensure that the activity of the encoded transcription factor is properly
directed towards driving an active and healthy articular chondrocyte
phenotype.
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UPDATE ON PHARMACOLOGIC MANAGEMENT OF OSTEOARTHRITIS
T.J. Schnitzer. Northwestern Univ. Feinberg Sch. of Med., Chicago, IL
Purpose: Provide an overview of new approaches to the management
of osteoarthritis (OA).
Methods: Review of the recent literature.
Results: A number of studies have recently concluded that have
addressed both symptom and disease modiﬁcation in OA. These studies
are expanding our understanding of the mechanisms associated with
pain generation and perception in OA as well as providing insight into
the importance of pathways of cartilage metabolic homeostasis,
respectively. Reduction of peripheral nerve input, attained by means of
monoclonal inhibition of nerve growth factor (NGF), a neurotrophin
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phase 3 clinical trials to result in signiﬁcant pain relief in OA, with the
magnitude of the pain relief being greater than what is observed with
NSAIDs in the same studies. Importantly, this approach has also been
shown to be effective in low back pain and is being investigated in
neuropathic pain models. Currently, the further development of this
class of drugs is on hold pending a more complete understanding of
their safety proﬁle. Centrally acting compounds, speciﬁcally serotonin-
norepinephrine reuptake inhibitors (SNRIs) have also been shown to
provide pain modiﬁcation in musculoskeletal pain conditions (OA, low
back pain), adding to the armamentarium available for the manage-
ment of these conditions. Novel topical agents as well as different
formulations of existing opioids are also being investigated at this time.
In terms of disease modiﬁcation, recent trials have examined the effects
of oral calcitonin on progression of structural disease as well as evalu-
ating inhibition of the inducible nitric oxide synthase pathway, believed
to be responsible for inﬂammatory and catabolic pathways in cartilage
leading to OA.
Conclusions: Inhibition of both peripheral and central pain pathways
has been shown to be effective at reducing pain and improving function
in people with OA. Further studies are needed to deﬁne the safety
proﬁle of therapy directed at inhibition of NGF. Disease modiﬁcation
remains a challenging goal, but a better understanding of the mecha-
nism of cartilage damage has allowed new agents to be considered for
study in this condition.
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NOVEL AND TARGETED THERAPIES FOR OA
N. Lane. Univ. of California at Davis, Ctr. for Musculoskeletal and Aging
Res., Sacramento, CA
The treatment of osteoarthritis (OA) and its associated pain remains an
unmet medical need, and our limited ability to effectively treat the
disease is due to deﬁcits in our understanding of both the pathophys-
iology of OA and the factors associated with the progression of the
disease. However, a number of novel and targeted treatments for
painful knee OA have been studied and demonstrate efﬁcacy, and
a selected number will be discussed.
Novel therapies. Recent studies of monoclonal antibodies that inhibit
nerve growth factor have been studied in moderate to severe knee
OA:tanezumab, injected every 8 weeks was found to reduce walking
knee pain nearly 50% more than placebo-treated subjects, and subjects
reported signiﬁcant improvement in pain and function over the 16
week study. A selective serotonin reuptake inhibitor approved for the
treatment of chronic painful conditions including ﬁbromyalgia
(duloxetine (60-120 mg/d)) was evaluated in an RCT of 250 subjects
with moderate knee OA for 13 weeks, and compared to a placebo
group it reduced knee pain by more than 50% and also improved
function. Exercise regimens have also had some success in the treat-
ment of pain from knee OA. Tai chi twice a week for 12 weeks was
evaluated in an RCT. WOMAC pain, WOMAC physical function and
physician VAS improved by 70% in the tai chi group from baseline, and
all outcome differences were p<0.05 compared to the attention-only
control group.
Targeted therapies. Since knee OA is frequently a localized disease, the
use of targeted local treatments has been studied. Intra-articular
injections of viscosupplementation have been used for the treatment of
knee pain. A comparator study of Hylan GF-20 (3 weekly injections) and
Sodium Hyaluronate (5 weekly injections) found signiﬁcant reduction
in knee pain by VAS, however it was sustained for 12 months in the
Hylan GF-20 group, and only for 6 months with Sodium Hyaluronate.
Interestingly, an RCTof Hylan GF-20 vs. placebowith treatments every 6
months for 24 months demonstrated a signiﬁcant beneﬁcial effect on
knee cartilage preservation measured by both cartilage volume and
cartilage defects. Onabotulinumtoxin A directly blocks peripheral
sensation through suppression of inﬂammatory neuropeptides arising
from sensory neurons, and can block both localized and central pain. An
RCT of onabotulinumtoxin A (100 U, 200 U) vs. methylprednisolone
40 mg found signiﬁcant reduction in VAS pain from baseline which was
sustained longer in the onabotulinumtoxin A group. Physical joint
distraction has been performed in a small study, and the reduction in
WOMAC pain subscale during the treatment was further improved and
maintained through 10 months post-distraction. Transplantation of
mesenchymal stem cells is also being evaluated but clinical studies
currently are lacking.I-9
PERIFIBRILLAR PROTEINS IN THE CARTILAGE EXTRACELLULAR
MATRIX
R. Wagener. Ctr. for Biochemistry, Univ. of Cologne, Cologne, Germany
To fulﬁl its function as a ﬂexible but simultaneously strongly supportive
tissue, a proper cartilage is dependent on the scaffold that is formed by
a network of large collagen ﬁbrils that are embedded in a proteoglycan
gel. However, to form, organise and maintain these macromolecular
networks accessory proteins are needed. A subset of such proteins is
found close to or at the surface of the collagen ﬁbrils, thereby creating
a “periﬁbrillar”matrix of a deﬁned composition. The periﬁbrillar matrix
may be of relevance for the regulation of collagen ﬁbrillogenesis and for
interactions between large collagen ﬁbrils, for their interactionwith the
proteoglycan gel and for interactions between large ﬁbrils and the
collagen VI containing microﬁbrils. Examples for pericellular proteins
are non-ﬁbril forming collagenmolecules of the FACIT type, small leucin
rich repeat proteoglycans as well as other abundant noncollagenous
proteins, like COMP (cartilage oligomeric matrix protein) and matrilins.
These all participate in the formation of ﬁbrillar or ﬁlamentous struc-
tures and mediate interactions between collagen ﬁbrils and other
matrix constituents. Interestingly, whereas the ablation of the Col2a1 or
the Acan genes in mice is perinatal lethal, the ablation of genes coding
for periﬁbrillar proteins leads to much milder phenotypes or shows
disturbances only detectable at the molecular level, perhaps indicating
redundancy due to the multiplicity of interconnections between these
proteins. In contrast, more severe phenotypes are observed when
mutations in genes coding for periﬁbrillar proteins affect protein
folding in the secretory pathway which leads to ER stress due to an
unfolded protein response. The lack of obvious phenotypes in single
knockouts of periﬁbrillar proteins can be partially overcome by the
generation of multiple knockouts, but even these mice often show only
mild phenotypes. Consequently, our current knowledge of the in vivo
function of pericellular proteins is predominantly based on in vitro
studies. We recently found that zebraﬁsh, a less complex vertebrate
animal model organism, is an alternative to study pericellular protein
function in vivo. When investigating the function of the prototypic
periﬁbrillar protein matrilin-1 in zebraﬁsh larvae we found that in
contrast to in mouse the knockdown of matrilin-1 by morpholino
antisense oligonucleotides has drastic consequences for cartilage
development and a proper cartilage is not formed. Instead, a mesen-
chymal tissue develops that lacks the major cartilage components
collagen II and aggrecan. Moreover, in severely affected larvae the cells
display “chondroptosis”, a variant of apoptosis in chondrocytes. Taken
together it is likely that the loss of matrilin-1 has an effect already
within the secretory pathway, where matrilin-1 may facilitate the
secretion of bulk extracellular matrix components. Nevertheless, it
remains obscure why this obvious phenotype occurs in zebraﬁsh and
not in mouse.
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OA BIOMARKERS: HOW WILL WE RECOGNIZE THE REAL MCCOY?
G. Moxley. Virginia Commonwealth Univ., Richmond, VA
This presentation aims to provide a conceptual overview for the OA
biomarkers session. A biomarker may be deﬁned thus: “a characteristic
[distinctive mark, trait, or feature] that is objectively measured and
evaluated as an indicator of normal biological processes, pathogenic
processes, or pharmacological responses to a therapeutic intervention.”
Implicit is that the biomarker lies along a pathogenetic pathway leading
to a clinical endpoint (how the patient feels, functions, or survives). A
surrogate marker may be thought of as a biomarker that approximates
a clinical endpoint and is expected to predict a clinical beneﬁt or harm.
One sees at once that current OA interventions are neither preventive
nor curative, and signiﬁcant obstacles block development. We can
expect that -omic and experimental biology investigations will outline
OA pathogenetic pathways, and so can anticipate ﬁnding biomarkers
among such pathways. Biomarkers could detect early OA, help under-
standing of pathogenesis, lead to prediction of outcome and alter
management, and aid drug development. In anticipation, a preliminary
classiﬁcation for OA biomarkers has been developed; its acronym BIPED
refers to Burden of disease, Investigative, Prognostic, Efﬁcacy of inter-
vention, and Diagnostic, with the later addition of Safety. To identify
useful biomarkers, we require clinical endpoints that deﬁne how an OA
patient feels and functions. The recent description of virtual joint
